~~<i id='01CDE26077'><strike id='01CDE26077'><tt id='01CDE26077'><pre id='01CDE26077'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：knowledge 2025-09-30 12:11:38 - browse：7713

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Future doctors should be trained to promote social change

hotspot

leisure time

Wikipedia

hotspot

knowledge

entertainment

AdobeThenewsiseverywhereinmysocialnewsfeedsthismorning:Apopularfaddietisapparentlylethal,scientificr

WSS

The untold story of TV’s first prescription drug ad

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Nurses recount patients attacks

Methadone treatment changes are coming. Do they go far enough?

Longer MASH drug regimen improved liver, Akero study finds

Neuroscience’s long legacy of racism

entertainment

leisure time

hotspot

Peter Hotez and the public health issue of online harassment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Medicare details structure of new drug price negotiation program

Lack of health data on LGBTQ+ people has serious consequences

Jerome Adams on the need for new antivirals for Covid

Streamlined flu vaccines recommended by FDA advisory panel

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

In age of alternative facts, a scholarly course on calling out crap

Immune cells and nerve overgrowth may explain recurring UTI pain

leisure time

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Pregnant women don't need prenatal multivitamins, study concludes

Microsoft's Peter Lee: Generative AI could help doctors be more human

Ancient Greek ideas underpin modern concepts of pregnancy

For AI in health care standards, federal regulators join with industry group

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Wikipedia

hotspot

knowledge

entertainment